CNS Generic Drugs: Prospects and Opportunities to 2012 - Market Research Reports - Research and Markets

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/603438

CNS Generic Drugs: Prospects and Opportunities to 2012

Description:

One of the fastest growing drug sectors in terms of product and market value, CNS presents the generics industry with much needed on-going product opportunities

ANTIDEPRESSANTS
Antidepressant sales in 2005 were approximately US$16.2 billion, and accounted for around 25% of the total CNS market. Global sales of the depression drugs analysed in this report in 2006 were worth some US$11.5 billion, with the largest selling, Effexor (venlafaxine), seeing sales worth US$3.7 billion. However, Effexor is now open to generic competition in the United States, with Teva having had an ANDA approved in 2006, and so it is likely that sales of the branded version will decline.

SCHIZOPHRENIA
Sales of schizophrenia drugs in 2005 were worth some US$15.5 billion, accounting for 23% of global CNS sales, making the segment the second largest CNS category. Global sales in 2006 of the schizophrenia drugs listed in this report were worth US$9.7 billion, with Zyprexa (olanzapine) and Risperdal (risperidone) accounting for US$4.4 billion and US$4.2 billion of this, respectively. Currently there are no generic equivalents to any of the schizophrenia drugs listed in the report in the US. However, a number of ANDAs for generic versions of Zyprexa and Risperdal have been tentatively approved.

NEURODEGENERATION
(ALZHEIMER’S DISEASE & PARKINSON’S DISEASE)
The neurodegenerative disorders segment is divided into two components, drugs for treating Alzheimer’s disease, and drugs for treating Parkinson’s disease. In 2005, some US$6.8 billion was spent on treatments for these two conditions, despite the fact that they only affect around 1% of the world’s population. In 2006, global sales of the five Alzheimer’s disease drugs listed in this report were worth some US$1.6 billion, whilst those for treating Parkinson’s disease were worth some US$1.5 billion.

MULTIPLE SCLEROSIS
The multiple sclerosis market was estimated to be worth some US$$4.8 billion in 2005. Global sales of the MS drugs listed in this report in 2006 were worth some US$5.8 billion. Of these, only one, Novantrone (mitoxantrone), is currently subject to generic competition in the US.

ADHD
The ADHD market had global sales of US$2.6 billion in 2005, and accounted for 3.8% of global CNS sales. Global sales for the drugs listed in this report were worth over US$2.8 billion, with the largest selling, Concerta (methylphenidate), having sales worth US$930 million.

INSOMNIA
The global market for insomnia products in 2005 was worth US$2.4 billion, and accounted for 3.5% of global CNS sales. In 2006, global sales for Ambien (zolpidem) were worth some US$2.7 billion. However, zolpidem has now been opened to generic competition in the US, with a number of companies gaining ANDA approvals for versions of the drug in 2007.

Among the 63 products evaluated in the report
- Abilify
- Aricept
- Azilect
- Carbatrol
- Copaxone
- Cymbalta
- Durotep
- Effexor
- Exelon
- Invega
- Keppra
- Lamictal
- Lyrica
- Namenda
- Prozac
- Rebif
- ReQuip
- Risperdal
- Seroxat
- Zoloft
- Zyprexa

Companies active in the CNS market are reviewed with respect to
- CNS Products
- Recent Product Approvals
- Financials
- Significant developments

Contents:

See PDF File below for a Detailed Table of Contents

Summary:

This important new strategic report from Espicom evaluates the CNS generic drug market and provides detailed assessment and forecast for leading products by value to 2012, patent expiry opportunities to 2015 and competitive evaluation. Providing…

Detailed assessment and forecast for leading products by value to 2012 and beyond

An assessment of patent expiry and challenges

Competitive evaluation

A review of products in late phase research which could impact generic developments

Patent expiry opportunities to 2015

All major sectors
Neurodegenerative Diseases
(Alzheimer’s and Parkinson’s Diseases)
Depression
Multiple Sclerosis
ADHD
Insomnia

Sales of the leading branded drugs used to treat the major CNS conditions could exceed US$70 billion in 2008, with a number of these losing patent protection in the coming years.

This important new strategic report evaluates the CNS generic drug market sector and answers key questions such as:

What is the patent and data exclusivity status of Shire’s ADHD drug Adderall?

What impact on sales of GSK’s Seroxat/Paxil will generic competition have from 2007?

What opportunities exist for Wyeth’s valuable SSNRI Effexor?

What strategies are sanofi-aventis employing in defence of its best selling insomnia treatment Ambien?

Only Exelon is currently available generically for the treatment of Alzheimer’s – what is the potential of the other leading treatments Aricept (Eisai), Razadyne (Janssen) and Namenda (Forest Labs)?

What’s in the pipeline? New branded products that will compete with generics in the future.

Why will sales of Eli Lilly’s Zyprexa remain constant over the next 5 years despite rising generic availability?

What are Dr Reddy’s CNS drug interests?

In 2007, Caraco Pharmaceuticals received 3 ANDA approvals for CNS drugs. What were they and in what dosages?

Companies Mentioned

- Apotex - Aurobindo Pharma - Barr Pharmaceuticals - Bedford Laboratories - Caraco Pharmaceutical Labs - Dr Reddy’s Laboratories - Impax Laboratories - Interpharm - KV Pharmaceutical - Mallinckrodt - Mikart - Mylan - Perrigo - Ranbaxy Laboratories - Roxane Laboratories - Sandoz - Sun Pharmaceutical Industries - Teva Pharmaceutical Industries - United Research Laboratories/Mutual Pharmaceutical Company - Watson Pharmaceuticals

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/603438

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed 11/10/2008 19:17:12

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com

Order information

Please verify that the product information is correct and select the format you require.


Product Name:
CNS Generic Drugs: Prospects and Opportunities to 2012
Web Address:
http://www.researchandmarkets.com/reports/603438
Office Code:
OCHKEPJOQQR

Report formats

Please enter the quantity of the report format you require.

	Format	Quantity	Price
	Electronic (PDF) - Single User		€1,495.00
	Hard Copy		€1,495.00 + EUR€ 50.00 Shipping/Handling *
	Electronic (Online Access) - Single User		€1,495.00

* Shipping/Handling is only charged once per order.

Contact information

Please enter all the information below in BLOCK CAPITALS.


	First Name:	Last Name:
	Email Address:
	Job Title:
	Organisation:
	Address:
	City:
	Postal/Zip Code:
	Country:
	Phone Number:
	Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Page 2 of 2
Printed 11/10/2008 19:17:12

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

	American Express
	Diners Club
	Master Card
	Visa


Cardholder Name:

Expiry Date:	/

Card Number:

CVV Security Code:

Issue Date:	/ (Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:


Account number:	83313083
Sort code:	98-53-30
Swift code:	ULSBIE2D
IBAN number:	IE78ULSB98533083313083
Bank Address:	Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:
	Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World